0.9461

2.96% 0.0272

After Hours: .91 -0.0361 -3.82%

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $0.9461, with a volume of 6.92M. It is up +2.96% in the last 24 hours and up +18.17% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Previous Close:

$0.9189

Open:

$0.97

24h Volume:

6.92M

Relative Volume:

1.61

Market Cap:

$145.89M

Revenue:

$126.33M

Net Income/Loss:

$-82.68M

P/E Ratio:

-0.763

EPS:

-1.24

Net Cash Flow:

$-79.98M

1W Performance:

-18.44%

1M Performance:

+18.17%

6M Performance:

+22.22%

1Y Performance:

-60.25%

1-Day Range:

$0.9412

$1.07

1-Week Range:

$0.798

$1.16

52-Week Range:

$0.54

$2.38

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

233

Twitter

@SeresTX

Next Earnings Date

2024-08-13

Latest SEC Filings

MCRB's Discussions on Twitter

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

05:15 AM

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A - StockTitan

05:15 AM

Sep 27, 2024

Seres shareholders question board on Nestlé takeover bid - Investing.com India

Sep 27, 2024

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé - StockTitan

Sep 27, 2024

Sep 26, 2024

Seres Therapeutics Stockholders Approve Sale of VOWST to Nestlé Health Science - citybiz

Sep 26, 2024

Seres Therapeutics shareholders approve sale of VOWST unit to Nestlé - Investing.com

Sep 26, 2024

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30 - The Manila Times

Sep 26, 2024

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30 - Yahoo Finance

Sep 26, 2024

Sep 25, 2024

Take off with Seres Therapeutics Inc (MCRB): Get ready for trading - SETE News

Sep 25, 2024

Affinity Asset Advisors LLC Sells 233,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Sep 25, 2024

Insider’s View: Deciphering Seres Therapeutics Inc (MCRB)’s Financial Health Through Ratios - The Dwinnex

Sep 25, 2024

Salesforce to buy its long-standing partner, data management firm Zoomin - Seeking Alpha

Sep 25, 2024

Sep 24, 2024

Samlyn Capital LLC Raises Stake in Merus (NASDAQ:MRUS) - Defense World

Sep 24, 2024

Sep 23, 2024

Seres Therapeutics Sees Unusually High Options Volume (NASDAQ:MCRB) - MarketBeat

Sep 23, 2024

Seres Therapeutics Inc: -59.35% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle

Sep 23, 2024

Daily Progress: Mersana Therapeutics Inc (MRSN) Drop -1.37, Closing at 2.16 - The Dwinnex

Sep 23, 2024

Was there any good news for Seres Therapeutics Inc (MCRB) stock in the last session? - US Post News

Sep 23, 2024

Seres Therapeutics’ Strategic Sale Of VOWST Warrants A Rating Upgrade (MCRB) - Seeking Alpha

Sep 23, 2024

Sep 22, 2024

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Sep 22, 2024

Sep 18, 2024

Analysts review Seres Therapeutics Inc’s rating - Knox Daily

Sep 18, 2024

Perhaps timely catching Seres Therapeutics Inc (MCRB) would be a good idea - SETE News

Sep 18, 2024

Sep 17, 2024

Company’s Banking Stock: Dissecting a 61.72% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Sep 17, 2024

Sep 16, 2024